Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Bonatti (Parma, Italy), V. Pitozzi (Parma, Italy), P. Caruso (Parma, Italy), S. Pontis (Parma, Italy), M. Pittelli (Parma, Italy), C. Frati (Parma, Italy), D. Madeddu (Parma, Italy), F. Quaini (Parma, Italy), C. Lagrasta (Parma, Italy), M. Civelli (Parma, Italy), S. Ottonello (Parma, Italy), G. Villetti (Parma, Italy), M. Trevisani (Parma, Italy), B. Montanini (Parma, Italy). Effect of Nintedanib in a rat model of bleomycin-induced lung fibrosis: a transcriptome analysis. 731

Member's Comments

No comment yet.

Related content which might interest you: Time-course analysis of bleomycin-induced lung fibrosis in the rat Source: International Congress 2018 – Pulmonary fibrosis: from models to patients Year: 2018 Quantitation of hydroxyproline in a mouse model of bleomycin-induced lung fibrosis: comparison with histological analysis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019 Evolution of biomechanical changes in a murine model of bleomycin-induced lung fibrosis: inflammation versus fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 396s Year: 2006 The effect of pravastatin on bleomycin-induced lung injury and fibrosis in mouse Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis Year: 2010 Comparative analysis of collagen quantification in the bleomycin mouse model of lung fibrosis Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Effect of Nintedanib in a rat model of lung fibrosis induced by single or double bleomycin administration Source: International Congress 2017 – The wide spectrum of ILDs Year: 2017 A longitudinal characterization of lymphangiogenesis in bleomycin-induced pulmonary fibrosis mouse model Source: Annual Congress 2012 - Fibrogenesis between epithelial injury and fibroblast proliferation Year: 2012 Chronic intermittent hypoxia exacerbates lung fibrosis in bleomycin-induced lung injury mouse model Source: International Congress 2018 – Sleep-disordered breathing: cardiovascular consequences, epidemiology, phenotypes and comorbidities Year: 2018 Correlation of Nintedanib efficacy on fibrotic lesion deposition and lung function within a rat IPF model Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Reduction of lung injury and fibrosis by human embrionic stem cells in a mouse model of silica-induced lung fibrosis Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Late Breaking Abstract - PRRX1 inhibition decreases fibrosis in the bleomycin-induced lung fibrosis model in mice Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 Effect of nintedanib on silica-induced lung inflammation and fibrosis in mice Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside Year: 2012 Late Breaking Abstract - MIF inhibition in a murine model of bleomycin-induced lung fibrosis Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension Year: 2018 Comparison of expression of napsin A and surfactant protein D in bleomycin-induced pulmonary fibrosis mouse model Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Aerobic exercise can impair lung fibrotic and functional response in a model of bleomycin-induced lung fibrosis: a time-dependent effect Source: International Congress 2017 – Novel pro- and anti-fibrotic mechanisms in pulmonary fibrosis Year: 2017 Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Pharmacological validation of a new IPF bleomycin-induced mouse model Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017 PBI-compound, a novel first-in-class anti-fibrotic compound, inhibits CTGF and collagen production in murine and human fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Effect of intratracheal administration of adipose-derived stromal cells on bleomycin-induced lung injury in a rat model Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015